Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SNP318 in Healthy Adults
NCT05792163Phase 1Completed
- Sponsor
- SciNeuro Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing SNP318 with Placebo (2 arms). Primary endpoint: Safety and tolerability assessed by adverse events up to 20 days. Started Mar 2023; status: completed.
02
Drugs
snp318
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05792163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792163.